Diarrhea after taking daclotinib is the most common adverse reaction to the drug. Dakotinib is a targeted drug for the treatment of EGFR mutations in non-small cell lung cancer, and the most common adverse reaction is diarrhea, with an incidence of about 87%. Most patients with diarrhea are able to tolerate it, and through dietary modification, all of them are also able to achieve relatively good therapeutic results. For more serious diarrhea, need to give medication, such as montelukast, etc., if necessary, need intravenous rehydration, pay attention to whether there are electrolyte disorders. Severe diarrhea, you should stop using the drug in a timely manner, after the symptoms are relieved, you can try again, if repeated severe diarrhea, you should consider replacing the targeted drugs.